Exploring novel polymeric NP platforms to improve systemic delivery to the lungs

Developing high-throughput tools to assess in vivo activity of NPs

Engaging the mononuclear phagocyte system (MPS) with “decoys” to alter the processing of therapeutic nanoparticles

Elucidating nanoparticle behavior within a diverse array of physiological conditions, considering variability across age, sex, disease states, and species

Developing high-throughput 3D cell culture models to screen therapeutics in physiologically relevant settings